Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen

Augenklinik und Poliklinik

Klinikum / Johannes Gutenberg-Universität Mainz

Forschungsprojekte
Ergebnisse pro Seite:  10

2015 - 2017

Untersuchung des neuroprotektiven Potentials von Autoantikörpern auf primäre retinale Ganglienzellen
  • Dr. KatharinaBell,
  • Prof. Dr. Dr. FranzGrus

2014 - 2019

IRISS (M-01-12-001): ILUVIEN Registry Safety Study
  • PD Dr. KatrinLorenz

2014 - 2017

Thea Monoprost (LT2345-PIV-02/13): Safety and Efficacy assessment of Monoprost® (unpreserved latanoprost) in comparison with Lumigan ® 0.01 % and Lumigan® 0.03% UD, in patients with open angle glaucoma or ocular hypertension, stabilized by all prostaglandin (except Monoprost®) with ocular surface intolerance.
  • PD Dr. KatrinLorenz

2014 - 2017

Prognostic Relevance of Antibodies and further Determination of Antibody Profiles Against retinal Antigenes
  • Prof. Dr. Dr. FranzGrus,
  • Dr. ChristinaKorb

2014 - 2017

RIVER
  • PD Dr. KatrinLorenz

2014 - 2017

Anti-angionetic Effects of Antibodies in a Laser induced choroidal neovascularization AMD animal model
  • Prof. Dr. Dr. Franz H.Grus

2014 - 2015

Sensimed TF-0902, TF1101 (retrospective): A retrospective chart review to investigate the potential of 24 hour SENSIMED Triggerfish® profile in predicting disease evolution in progressing primary open angle glaucoma patients
  • PD Dr. KatrinLorenz

2014 - 2017

JETREA (TG-MV-017): Use of Intravitreal JETREA® in Clinical Practice: A European Prospective Drug Utilisation Study (TG-MV-017)
  • PD Dr. KatrinLorenz

2014 - 2016

Eclipse (OPH1003 212165): A PHASE 3 RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS ADMINISTRATION OF FOVISTATM (ANTI PDGF-B PEGYLATED APTAMER) ADMINISTERED IN COMBINATION WITH LUCENTIS® COMPARED TO LUCENTIS® MONOTHERAPY IN SUBJECTS WITH SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
  • PD Dr. KatrinLorenz

2014 - 2020

COLUMBUS (CMEK162B2301) - A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma
  • PD Dr. KatrinLorenz